SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition
Science Advances · 13.12.2024 · 10 (50)
DOI: 10.1126/sciadv.adq4274 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 13.12.2024. Verfasst von Xinxin Song und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA. Hauptthemen laut MEDLINE: src-Family Kinases, Drug Resistance, Neoplasm, Proto-Oncogene Proteins p21(ras), Protein Kinase Inhibitors. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, BLRD VA.
Abstract (Originalsprache)
Direct targeting of the KRAS-G12C –mutant protein using covalent inhibitors (G12Ci) acts on human non–small cell lung cancer (NSCLC). However, drug resistance is an emerging concern in this approach. Here, we show that MRTX849, a covalent inhibitor targeting the KRAS-G12C mutation, leads to the reactivation of the mitogen-activated protein kinase signaling pathway in MRTX849-resistant NSCLC and pancreatic ductal adenocarcinoma. A genome-wide CRISPR screen revealed that the adenosine triphosphate binding cassette transporter ABCC1 mediates MRTX849 resistance. Functional studies demonstrated that the transcription factor JUN drives ABCC1 expression, resulting in multidrug resistance. An unbiased drug screen identified the tyrosine kinase inhibitor dasatinib that potentiates MRTX849 efficacy by inhibiting SRC-dependent JUN activation, avoiding multidrug resistance and tumor suppression in vitro as well as in suitable preclinical mouse models and patient-derived organoids. SRC inhibitors (DGY-06-116, dasatinib, and bosutinib) also exhibit synergistic effects with MRTX849 in eliminating various tumor cell lines carrying KRAS-G12C mutations. Thus, SRC inhibitors amplify the therapeutic utility of G12Ci.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA.
- Departments of Biochemistry and Radiation Oncology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
- Hamon Center for Therapeutic Oncology Research, Department of Pharmacology, Department of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA.
- Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM U1138, Institut Universitaire de France, Paris, France.
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.
- Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
ORCID-Profile: Xinxin Song, Zhuan Zhou, Ammar Elmezayen, Runliu Wu, Chunhua Yu, Boning Gao, John D Minna, Kenneth D Westover, Herbert J Zeh, Guido Kroemer, Lynn E Heasley, Rui Kang, Daolin Tang
Förderung
- NCI NIH HHS
- BLRD VA
Zitieren
APA
Song, X., Zhou, Z., Elmezayen, A., Wu, R., Yu, C., Gao, B., Minna, J. D., Westover, K. D., Zeh, H. J., Kroemer, G., Heasley, L. E., Kang, R., & Tang, D. (2024). SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition. Science Advances, 10(50). https://doi.org/10.1126/sciadv.adq4274
Vancouver
Song X, Zhou Z, Elmezayen A, Wu R, Yu C, Gao B, et al. SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition. Science Advances. 2024;10(50). doi:10.1126/sciadv.adq4274
BibTeX
@article{Song2024,
author = {Song, Xinxin and Zhou, Zhuan and Elmezayen, Ammar and Wu, Runliu and Yu, Chunhua and Gao, Boning and Minna, John D and Westover, Kenneth D and Zeh, Herbert J and Kroemer, Guido and Heasley, Lynn E and Kang, Rui and Tang, Daolin},
title = {SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition},
journal = {Science Advances},
year = {2024},
volume = {10},
number = {50},
doi = {10.1126/sciadv.adq4274}
}
EUVIMED